awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q52659225-48A61A61-35E9-4AFE-856D-42477C6BE894
Q52659225-48A61A61-35E9-4AFE-856D-42477C6BE894
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52659225-48A61A61-35E9-4AFE-856D-42477C6BE894
#2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models.
P2860
Q52659225-48A61A61-35E9-4AFE-856D-42477C6BE894
BestRank
Statement
http://www.wikidata.org/entity/statement/Q52659225-48A61A61-35E9-4AFE-856D-42477C6BE894
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a4ee79d596e97f853b5e649642465d77b68fbc97
P2860
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.